HOFSETH BIOCARE ASA: årsregnskap 2021 vs 2020
Grew 28% on revenue, cash halved-plus
approved 2022-03-25; registry 2022-06-25; journal 2022 506065
Summary
What changed
Comparing Årsregnskap 2021 with 2020 for HOFSETH BIOCARE ASA. Revenue 68.71m NOK → 88.05m NOK (+28.1%). Net result -105.28m NOK → -122.24m NOK. Equity 261.6k NOK → 142.76m NOK.
On the constructive side: revenue rose; equity strengthened; current ratio back above 1×. Pressures included: operating result weakened; net result weakened; cash fell.
Also worth watching: sharp cash drawdown; paid-in equity reduced; payroll increased. All figures are taken from the published annual accounts for HOFSETH BIOCARE ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 68.71m NOK to 88.05m NOK (+28.1% YoY). Calculated
-
↑
Equity strengthened
Book equity 261.6k NOK → 142.76m NOK (equity ratio 58.8% → 36.2%). Calculated
-
↑
Current ratio back above 1×
Current ratio 0.00× → 1124.56×. Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -91.77m NOK → -110.71m NOK (op. margin -133.6% → -125.7%). Calculated
-
↓
Net result weakened
Net result -105.28m NOK → -122.24m NOK (net margin -153.2% → -138.8%). Calculated
-
↓
Cash fell
Bank deposits 171.78m NOK → 48.36m NOK (-71.8% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (171.78m NOK → 48.36m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 248.97m NOK → 142.76m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 36.43m NOK → 37.80m NOK (53% → 43% of revenue). Calculated
-
·
Book investments changed
Investment / intangible book value 26.92m NOK → 18.76m NOK. Reported fact